Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Universal cell-based
cancer immunotherapy
IPO Mar 2018 (NASDAQ: UMRX)

Next generation
synthetic biology platform
for novel therapeutics

Next-generation antibody therapies
targeting the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Enhancing synaptic integrity
for treatment of
neurologic disorders

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Small molecule
drug design
using statistical modeling

Breakthrough computer-aided
drug design
for transformative medicines

Novel therapeutics
targeting
diseases of aging

Discovering new medicines
for severe
neurodegenerative diseases

Minimally invasive
heart valve
devices

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Bispecific antibodies
to improve the treatment
of serious diseases

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Cell and gene therapies for
rare diseases and cancer
IPO Jun 2018 (NASDAQ: AVRO)

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

New class of
regulated cell and
gene therapies

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

First-in-class
RNA therapies
for severe genetic diseases

Preventing axonal degeneration
in patients with
neurological diseases

Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases

Creating breakthrough
therapies for neurological
and psychiatric conditions

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Stimulating the innate and
adaptive immune system in a
novel approach to treat cancer

Titratable, re-dosable genetic
medicines with drug-like properties
for patients with genetic diseases

Novel MetAP2 therapeutics to transform
complex metabolic disorders –
IPO June 2014 (NASDAQ: ZFGN)

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Restoring metabolic balance
to treat NASH and other
serious metabolic diseases

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Highly-potent, targeted, and
combinable immuno-oncology
therapeutics